India’s TB patients can finally celebrate the end of Johnson & Johnson’s monopoly disguised as charity

Every great Indian enterprise has a story worth telling in full.

With The Intermission, The Ken's flagship long-form podcast, hosts Rohin Dharmakumar and Seetharaman G do exactly that—tracing the origins, turning points, and defining strategies of the companies that shaped modern India. 

Built on exhaustive research and proprietary interviews, each episode unfolds as a richly reported narrative. 

The first episode drops on March 23! Stay tuned!

India’s patent office decided to reject pharma giant Johnson &Johnson’s appeal to extend the patent for a life-saving TB medicine called bedaquiline which is used to treat those with drug resistant infections. 

But for a long time before this, Johnson & Johnson was enjoying a monopoly in India. Generic manufacturers could not make this life-saving medicine. The Indian government too, at the time, had decided to protect the pharma giant.

Not just that, Johnson & Johnson was also conveniently projecting itself as a charitable organisation through its health programmes.

What does the Indian govt’s decision mean for TB patients in India now?

🚨The Ken's Zero Shot podcast is hosting a live event! This is a speculative yet realistic discussion built around one premise: what happens when AI agents take off in India? How will they rewire existing habits, business models and profit pools? Since nobody knows for sure, we won't pretend to have all the answers. Instead we are going to break the narrative. Click here for details.